• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV‑2/COVID‑19 pandemic, including recommendations for COVID‑19 vaccination].

作者信息

Specker Christof, Aries Peer, Braun Jürgen, Burmester Gerd, Fischer-Betz Rebecca, Hasseli Rebecca, Holle Julia, Hoyer Bimba Franziska, Iking-Konert Christof, Krause Andreas, Krüger Klaus, Krusche Martin, Leipe Jan, Lorenz Hanns-Martin, Moosig Frank, Schmale-Grede Rotraud, Schneider Matthias, Strangfeld Anja, Voll Reinhard, Voormann Anna, Wagner Ulf, Schulze-Koops Hendrik

机构信息

Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.

Klinik für Rheumatologie und Klinische Immunologie, Kliniken Essen-Mitte, Pattbergstr. 2, 45239, Essen, Deutschland.

出版信息

Z Rheumatol. 2021 Aug;80(6):570-587. doi: 10.1007/s00393-021-01056-6.

DOI:10.1007/s00393-021-01056-6
PMID:34309739
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8311067/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ace/8311067/375fbcb9cdc6/393_2021_1056_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ace/8311067/375fbcb9cdc6/393_2021_1056_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ace/8311067/375fbcb9cdc6/393_2021_1056_Fig1_HTML.jpg

相似文献

1
[Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV‑2/COVID‑19 pandemic, including recommendations for COVID‑19 vaccination].[德国风湿病学会关于在SARS-CoV-2/COVID-19大流行背景下照顾炎性风湿性疾病患者的最新建议，包括COVID-19疫苗接种建议]
Z Rheumatol. 2021 Aug;80(6):570-587. doi: 10.1007/s00393-021-01056-6.
2
Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination.德国风湿病学会关于在SARS-CoV-2/COVID-19大流行背景下照顾炎性风湿性疾病患者的最新建议，包括COVID-19疫苗接种建议。
Z Rheumatol. 2021 Dec;80(Suppl 2):33-48. doi: 10.1007/s00393-021-01055-7. Epub 2021 Sep 7.
3
Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2-methodology, key messages and justifying information.德国风湿病学会关于在2019冠状病毒病时期照顾炎性风湿性疾病患者的更新建议——方法、关键信息及论证依据
Rheumatology (Oxford). 2021 May 14;60(5):2128-2133. doi: 10.1093/rheumatology/keab072.
4
[German registry www.Covid19-Rheuma.de : Status report after 1 year of the pandemic].[德国登记处www.Covid19 - Rheuma.de：大流行一年后的现状报告]
Z Rheumatol. 2021 Sep;80(7):641-646. doi: 10.1007/s00393-021-01034-y. Epub 2021 Jul 1.
5
[SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments].[严重急性呼吸综合征冠状病毒2与风湿性疾病：严重急性呼吸综合征冠状病毒2大流行对炎性风湿性疾病患者的影响。风湿学会行动建议与不同抗风湿治疗风险评估的比较]
Z Rheumatol. 2020 Sep;79(7):686-691. doi: 10.1007/s00393-020-00878-0. Epub 2020 Aug 26.
6
[Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020].[德国风湿病学会关于在SARS-CoV-2/COVID-19大流行背景下炎症性风湿性疾病患者管理的建议 - 2020年7月更新]
Z Rheumatol. 2020 Sep;79(7):679-685. doi: 10.1007/s00393-020-00851-x.
7
[Prospective monitoring of a university rheumatology outpatient clinic throughout the first wave of the COVID-19 pandemic : What lessons can be learned?].[在新冠疫情第一波期间对大学风湿病门诊进行前瞻性监测：能吸取哪些教训？]
Z Rheumatol. 2021 Jun;80(5):408-417. doi: 10.1007/s00393-020-00935-8. Epub 2020 Nov 30.
8
Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic.德国风湿病学会（DGRh eV）关于SARS-CoV-2/COVID-19大流行期间炎性风湿性疾病患者管理的初步建议。
Ann Rheum Dis. 2020 Jun;79(6):840-842. doi: 10.1136/annrheumdis-2020-217628. Epub 2020 Apr 28.
9
[Current guidance of the German Society of Rheumatology for the care of patients with rheumatic diseases during the SARS-CoV-2/Covid 19 pandemic].[德国风湿病学会关于SARS-CoV-2/新冠疫情期间风湿病患者护理的当前指南]
Z Rheumatol. 2020 May;79(4):385-388. doi: 10.1007/s00393-020-00799-y.
10
[Vaccination against SARS-CoV-2 in inflammatory rheumatic diseases : Recommendations of the German Society for Rheumatology for physicians and patients].[炎症性风湿性疾病中针对严重急性呼吸综合征冠状病毒2的疫苗接种：德国风湿病学会给医生和患者的建议]
Z Rheumatol. 2021 Feb;80(1):43-44. doi: 10.1007/s00393-020-00955-4. Epub 2021 Jan 12.

引用本文的文献

1
Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database.在类风湿性关节炎患者的真实世界队列中，Janus激酶抑制剂比生物制剂具有更长的药物生存期——来自RHADAR数据库的一项回顾性分析。
Rheumatol Int. 2025 Apr 15;45(5):100. doi: 10.1007/s00296-025-05859-7.
2
[The German Society for Rheumatology and Clinical Immunology (DGRh) and the COVID-19 pandemic].[德国风湿病与临床免疫学协会（DGRh）与新冠疫情]
Z Rheumatol. 2024 Sep;83(7):520-527. doi: 10.1007/s00393-024-01540-9. Epub 2024 Jul 15.
3
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.

本文引用的文献

1
Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series.霉酚酸临时停药增强风湿性和肌肉骨骼疾病患者对SARS-CoV-2疫苗的体液免疫反应：病例系列
Ann Rheum Dis. 2022 Feb;81(2):293-295. doi: 10.1136/annrheumdis-2021-221252. Epub 2021 Sep 23.
2
Prothrombotic immune thrombocytopenia after COVID-19 vaccination.接种 COVID-19 疫苗后的促血栓形成免疫性血小板减少症。
Blood. 2021 Jul 29;138(4):350-353. doi: 10.1182/blood.2021011958.
3
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
疫苗类型和免疫抑制治疗，但不是诊断，对风湿性疾病患者 COVID-19 疫苗接种后的抗体反应有重要影响。
RMD Open. 2022 Dec;8(2). doi: 10.1136/rmdopen-2022-002650.
4
Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases.停止甲氨蝶呤治疗可提高老年风湿病患者 COVID-19 疫苗的免疫原性。
Ann Rheum Dis. 2022 Jun;81(6):881-888. doi: 10.1136/annrheumdis-2021-221876. Epub 2022 Mar 14.
5
[COVID-19 in Routine Rheumatologic Care].[常规风湿病护理中的新型冠状病毒肺炎]
Rheuma Plus. 2021;20(6):267-271. doi: 10.1007/s12688-021-00474-3. Epub 2021 Nov 1.
6
[Are SARS-CoV-2 reactive T cells detectable and potentially protective in patients under anti-CD20 treatment with an impaired humoral response?].[在体液反应受损的接受抗CD20治疗的患者中，是否可检测到针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的反应性T细胞并具有潜在保护作用？]
Z Rheumatol. 2021 Nov;80(9):879-883. doi: 10.1007/s00393-021-01083-3. Epub 2021 Sep 16.
生物制剂或靶向合成 DMARDs 的基线使用与类风湿关节炎 COVID-19 严重程度的相关性：来自 COVID-19 全球风湿病联盟医生登记处的结果。
Ann Rheum Dis. 2021 Sep;80(9):1137-1146. doi: 10.1136/annrheumdis-2021-220418. Epub 2021 May 28.
4
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.甲氨蝶呤会削弱免疫介导的炎症性疾病患者对BNT162b2 mRNA新冠疫苗的免疫原性。
Ann Rheum Dis. 2021 Oct;80(10):1339-1344. doi: 10.1136/annrheumdis-2021-220597. Epub 2021 May 25.
5
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
6
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.利妥昔单抗而非其他抗风湿疗法，与风湿性疾病患者对SARS-CoV-2疫苗的血清学反应受损有关。
Ann Rheum Dis. 2021 Oct;80(10):1357-1359. doi: 10.1136/annrheumdis-2021-220604. Epub 2021 May 11.
7
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.未治疗、常规治疗和抗细胞因子治疗的免疫介导性炎症性疾病患者的 SARS-CoV-2 疫苗反应。
Ann Rheum Dis. 2021 Oct;80(10):1312-1316. doi: 10.1136/annrheumdis-2021-220461. Epub 2021 May 6.
8
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.利妥昔单抗治疗患者的新型冠状病毒2型疫苗接种：体液免疫受损但细胞免疫反应可诱导的证据
Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.
9
An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination.一项观察性研究旨在确定挪威医护人员在接种 COVID-19 疫苗后血小板减少症和抗 PF4/多阴离子抗体的流行情况。
J Thromb Haemost. 2021 Jul;19(7):1813-1818. doi: 10.1111/jth.15352. Epub 2021 May 18.
10
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.mRNA 新冠疫苗在孕妇中的初步安全性研究结果。
N Engl J Med. 2021 Jun 17;384(24):2273-2282. doi: 10.1056/NEJMoa2104983. Epub 2021 Apr 21.